Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GXV-005
- Development stage
- Preclinical
- Lead developer
- GEXVal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GXV-005 is an investigational small molecule calcium-sensing receptor (CaSR) antagonist (calcilytic) originally developed by Takeda and currently being developed by GEXVal. It is part of GEXVal's CaSR franchise, which also includes GXV-002 and GXV-004. GXV-005 is being developed for the treatment of pulmonary arterial hypertension (PAH), rare genetic cardiovascular diseases, and various forms of heart failure, including acute decompensated heart failure (ADHF), heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF). The drug is currently in the Discovery/IND-enabling stage of development.
02
Targets
CaSR (Extracellular calcium-sensing receptor)
Beyond the preview
Go deeper on GXV-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GXV-005.